The Association of the British Pharmaceutical Industry (ABPI) has released research showing that the amount of capital invested alongside corporate venture capital (CVC) in UK biotech increased six-fold between 2010 and 2015.
Investment
Key findings from the report, ‘The rise of Corporate Venture Capital investment in UK biotech’, were that during 2015 financing rounds involving CVC amounted to $647 million out of $1033 million invested in UK life sciences companies; and UK companies closed 68% of European financing rounds involving CVC in 2016.